#cytokines as #biomarkers for therapeutic success in #NSCLC #nsclctrial #Immunotherapy #pd1 #pdl1 utilizing #MachineLearming , link to downloadable PDF https://bit.ly/3NTxfTt

Sensitizing tumors to anti-#pd1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3
📌 https://pubmed.ncbi.nlm.nih.gov/34887262/
📌 https://pubmed.ncbi.nlm.nih.gov/36787694/

RT @profcelentyx@twitter.com

Major #Immunotherapy #Biomarker Advance | Is this the Ki(67) to Predicting #ICB Responses in #Melanoma 🤔 | #Peripheral Phenotypes Stratifying #PD1 #Blockade Outcomes 👍 | Important New Study from @NatalieEdner@twitter.com et al @LucyWalkerlab@twitter.com now @IMTadvances@twitter.com 👏 | https://academic.oup.com/immunotherapyadv/advance-article/doi/10.1093/immadv/ltad001/6972738?searchresult=1

🐦🔗: https://twitter.com/profcelentyx/status/1613138541214662657

Role of #PCIF1-mediated 5′-cap N6-#methyladeonsine #m6A #mRNA #methylation in #colorectalcancer and anti-#PD1 #immunotherapy

New article by Tariq Rana and colleagues at UCSD

https://www.embopress.org/doi/10.15252/embj.2022111673

Vista antibody is on a fast track to be developed as a checkpoint blockade agent by #kineta #kinetapharma in cancer. Very nice data showing reversal of negative immune signals similar to #PD1 Peomoter is responsive to hypoxia. Protein activated in low pH #immunotherapy #ASH22 #checkpoint

Thirty years ago, in November 1992, Ishida, Honjo and their collaborators reported the discovery of the #PD1 gene in @embojournal

https://www.embopress.org/doi/abs/10.1002/j.1460-2075.1992.tb05481.x

I spoke with Tasuku Honjo, Pierre Golstein (whose team first cloned #CTLA4) & Facundo Batista about the discovery earlier this year.
The initial project had absolutely nothing to do with checkpoints or #immunotherapy

Listen to the full #EMBOPodcast episode at the link below or on pretty much any podcast app

#Immunology #HistoryScience #Cancer #CellDeath

https://www.embo.org/podcasts/from-cell-death-to-cancer-immunotherapy/

Thirty years ago, in November 1992, Ishida, Honjo and their collaborators reported the discovery of the #PD1 gene in @embojournal

https://www.embopress.org/doi/abs/10.1002/j.1460-2075.1992.tb05481.x

I spoke with Tasuku Honjo, Pierre Golstein (whose team first cloned #CTLA4) & Facundo Batista about the discovery. The initial project had absolutely nothing to do with checkpoints or #immunotherapy

Listen to the full #EMBOPodcast episode at the link below or on pretty much any podcast app

#Immunology #HistoryScience #Cancer #CellDeath

https://www.embo.org/podcasts/from-cell-death-to-cancer-immunotherapy/

#Immunology #Immunotherapy
#checkpointinhibitors

"In this Review we mark the tenth anniversary of the approval of ipilimumab and discuss the foundational scientific history of ICB, together with the history of the discovery, development and elucidation of the mechanism of action of the first generation of drugs targeting the #CTLA4 and #PD1 pathways."

https://www.nature.com/articles/s41573-021-00345-8

RT @CancerDoc: #NLRP3 #inflammasome is a double-edged sword in #cancer. NLRP3 activation can be associated with hyper-progression on #PD1 #immunotherapy https://www.science.org/doi/abs/10.1126/scitranslmed.abq7019
#oncology

#NLRP3 #inflammasome is a double-edged sword in #cancer. NLRP3 activation can be associated with hyper-progression on #PD1 #immunotherapy https://www.science.org/doi/abs/10.1126/scitranslmed.abq7019

This is an excellent landscape map for #cell #therapy #immunotherapy #CART #TCR #cancer. Created by Wells Fargo IG and Posted recently to LI by Basem Goueli. As noted by Jun Tang, The graphic concept originated from Vanessa Lucey from CRI and @IraMellman and I published on it for #PDL1 #PD1 in Nature in 2018 as part of the Immune set point manuscript. Incredible how the field has developed over the last several years.